The largest-ever prospective study in the detection of malignant melanoma shows convincing results for Nevisense.
“The number one advantage regarding Nevisense is that it backs up my decision and provides me with more certainty in whether or not to excise a lesion.”
Dr. Isabel Gahlen, Germany
AAD Annual Meeting
San Diego, USA
February 16-20, 2018